Prelude Therapeutics (PRLD) Stock Forecast, Price Target & Predictions
PRLD Stock Forecast
Prelude Therapeutics stock forecast is as follows: an average price target of $6.25 (represents a 563.48% upside from PRLD’s last price of $0.94) and a rating consensus of 'Sell', based on 3 wall street analysts offering a 1-year stock forecast.
PRLD Price Target
The average price target for Prelude Therapeutics (PRLD) is $6.25 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $3.00. This represents a potential 563.48% upside from PRLD's last price of $0.94.
PRLD Analyst Ratings
According to 3 Wall Street analysts, Prelude Therapeutics's rating consensus is 'Sell'. The analyst rating breakdown for PRLD stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 0 'Hold' (0.00%), 2 'Sell' (66.67%), and 0 'Strong Sell' (0.00%).
Prelude Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 10, 2024 | Robert Burns | H.C. Wainwright | $5.00 | $5.17 | -3.29% | 430.79% |
| Jun 20, 2024 | Peter Lawson | Barclays | $3.00 | $3.87 | -22.48% | 218.47% |
| Mar 13, 2024 | Reni Benjamin | JMP Securities | $7.00 | $4.62 | 51.52% | 643.10% |
| Nov 17, 2022 | - | H.C. Wainwright | $15.00 | $7.70 | 94.81% | 1492.36% |
| Nov 15, 2022 | - | Morgan Stanley | $10.00 | $8.10 | 23.46% | 961.57% |
The latest Prelude Therapeutics stock forecast, released on Sep 10, 2024 by Robert Burns from H.C. Wainwright, set a price target of $5.00, which represents a -3.29% decrease from the stock price at the time of the forecast ($5.17), and a 430.79% increase from PRLD last price ($0.94).
Prelude Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $5.00 | $5.00 |
| Last Closing Price | $0.94 | $0.94 | $0.94 |
| Upside/Downside | -100.00% | 430.79% | 430.79% |
In the current month, the average price target of Prelude Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Prelude Therapeutics's last price of $0.94. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 19, 2024 | H.C. Wainwright | Neutral | Buy | Upgrade |
| Sep 10, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Jun 20, 2024 | Barclays | Equal-Weight | Underweight | Downgrade |
| Dec 19, 2023 | Morgan Stanley | Equal-Weight | Underweight | Downgrade |
| Nov 15, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Feb 28, 2022 | Barclays | - | Equal-Weight | Downgrade |
Prelude Therapeutics's last stock rating was published by H.C. Wainwright on Sep 19, 2024. The company Upgrade its PRLD rating from "Neutral" to "Buy".
Prelude Therapeutics Financial Forecast
Prelude Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | - |
| High Forecast | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | - |
| Low Forecast | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | - |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | - |
| Surprise % | - | - | - | - | - | - | - |
Prelude Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PRLD's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Prelude Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict PRLD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Prelude Therapeutics's previous annual EBITDA (undefined) of $NaN.
Prelude Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-33.38M | $-33.00M | $-32.24M | $-32.62M | $-35.96M | $-35.80M | $-32.58M |
| High Forecast | $-33.38M | $-33.00M | $-32.24M | $-32.62M | $-35.22M | $-35.80M | $-32.58M |
| Low Forecast | $-33.38M | $-33.00M | $-32.24M | $-32.62M | $-36.69M | $-35.80M | $-32.58M |
| Surprise % | - | - | - | - | - | - | - |
Prelude Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PRLD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Prelude Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Prelude Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PRLD last annual SG&A of $NaN (undefined).
Prelude Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.44 | $-0.43 | $-0.42 | $-0.43 | $-0.47 | $-0.47 | $-0.43 |
| High Forecast | $-0.44 | $-0.43 | $-0.42 | $-0.43 | $-0.46 | $-0.47 | $-0.43 |
| Low Forecast | $-0.44 | $-0.43 | $-0.42 | $-0.43 | $-0.48 | $-0.47 | $-0.43 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Prelude Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PRLD previous annual EPS of $NaN (undefined).
Prelude Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| PASG | Passage Bio | $0.47 | $6.00 | 1176.60% | Buy |
| STTK | Shattuck Labs | $1.11 | $12.00 | 981.08% | Hold |
| ANTX | AN2 Therapeutics | $1.00 | $8.75 | 775.00% | Buy |
| PEPG | PepGen | $4.13 | $29.50 | 614.29% | Buy |
| PRLD | Prelude Therapeutics | $0.94 | $6.25 | 564.89% | Sell |
| BDTX | Black Diamond Therapeutics | $2.50 | $14.75 | 490.00% | Buy |
| MOLN | Molecular Partners | $5.83 | $29.00 | 397.43% | Buy |
| CCCC | C4 Therapeutics | $4.20 | $13.50 | 221.43% | Buy |
| RZLT | Rezolute | $4.87 | $13.50 | 177.21% | Buy |
| MLYS | Mineralys Therapeutics | $11.40 | $30.00 | 163.16% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| FHTX | Foghorn Therapeutics | $7.71 | $16.33 | 111.80% | Buy |
| PHVS | Pharvaris | $20.92 | $39.67 | 89.63% | Buy |
| NRIX | Nurix Therapeutics | $21.79 | $32.20 | 47.77% | Buy |
| KYMR | Kymera Therapeutics | $42.41 | $51.50 | 21.43% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $54.24 | $60.63 | 11.78% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |